Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.
Despite more than 25 years of research, the molecular targets of quinoline-3-carboxamides have been elusive although these compounds are currently in Phase II and III development for treatment of autoimmune/inflammatory diseases in humans. Using photoaffinity cross-linking of a radioactively labelle...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d9b0cf5ec37a4cefa5970058e75fe613 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d9b0cf5ec37a4cefa5970058e75fe613 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d9b0cf5ec37a4cefa5970058e75fe6132021-11-25T05:34:11ZIdentification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.1544-91731545-788510.1371/journal.pbio.1000097https://doaj.org/article/d9b0cf5ec37a4cefa5970058e75fe6132009-04-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19402754/?tool=EBIhttps://doaj.org/toc/1544-9173https://doaj.org/toc/1545-7885Despite more than 25 years of research, the molecular targets of quinoline-3-carboxamides have been elusive although these compounds are currently in Phase II and III development for treatment of autoimmune/inflammatory diseases in humans. Using photoaffinity cross-linking of a radioactively labelled quinoline-3-carboxamide compound, we could determine a direct association between human S100A9 and quinoline-3-carboxamides. This interaction was strictly dependent on both Zn++ and Ca++. We also show that S100A9 in the presence of Zn++ and Ca++ is an efficient ligand of receptor for advanced glycation end products (RAGE) and also an endogenous Toll ligand in that it shows a highly specific interaction with TLR4/MD2. Both these interactions are inhibited by quinoline-3-carboxamides. A clear structure-activity relationship (SAR) emerged with regard to the binding of quinoline-3-carboxamides to S100A9, as well as these compounds potency to inhibit interactions with RAGE or TLR4/MD2. The same SAR was observed when the compound's ability to inhibit acute experimental autoimmune encephalomyelitis in mice in vivo was analysed. Quinoline-3-carboxamides would also inhibit TNFalpha release in a S100A9-dependent model in vivo, as would antibodies raised against the quinoline-3-carboxamide-binding domain of S100A9. Thus, S100A9 appears to be a focal molecule in the control of autoimmune disease via its interactions with proinflammatory mediators. The specific binding of quinoline-3-carboxamides to S100A9 explains the immunomodulatory activity of this class of compounds and defines S100A9 as a novel target for treatment of human autoimmune diseases.Per BjörkAnders BjörkThomas VoglMartin StenströmDavid LibergAnders OlssonJohannes RothFredrik IvarsTomas LeandersonPublic Library of Science (PLoS)articleBiology (General)QH301-705.5ENPLoS Biology, Vol 7, Iss 4, p e97 (2009) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Biology (General) QH301-705.5 |
| spellingShingle |
Biology (General) QH301-705.5 Per Björk Anders Björk Thomas Vogl Martin Stenström David Liberg Anders Olsson Johannes Roth Fredrik Ivars Tomas Leanderson Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. |
| description |
Despite more than 25 years of research, the molecular targets of quinoline-3-carboxamides have been elusive although these compounds are currently in Phase II and III development for treatment of autoimmune/inflammatory diseases in humans. Using photoaffinity cross-linking of a radioactively labelled quinoline-3-carboxamide compound, we could determine a direct association between human S100A9 and quinoline-3-carboxamides. This interaction was strictly dependent on both Zn++ and Ca++. We also show that S100A9 in the presence of Zn++ and Ca++ is an efficient ligand of receptor for advanced glycation end products (RAGE) and also an endogenous Toll ligand in that it shows a highly specific interaction with TLR4/MD2. Both these interactions are inhibited by quinoline-3-carboxamides. A clear structure-activity relationship (SAR) emerged with regard to the binding of quinoline-3-carboxamides to S100A9, as well as these compounds potency to inhibit interactions with RAGE or TLR4/MD2. The same SAR was observed when the compound's ability to inhibit acute experimental autoimmune encephalomyelitis in mice in vivo was analysed. Quinoline-3-carboxamides would also inhibit TNFalpha release in a S100A9-dependent model in vivo, as would antibodies raised against the quinoline-3-carboxamide-binding domain of S100A9. Thus, S100A9 appears to be a focal molecule in the control of autoimmune disease via its interactions with proinflammatory mediators. The specific binding of quinoline-3-carboxamides to S100A9 explains the immunomodulatory activity of this class of compounds and defines S100A9 as a novel target for treatment of human autoimmune diseases. |
| format |
article |
| author |
Per Björk Anders Björk Thomas Vogl Martin Stenström David Liberg Anders Olsson Johannes Roth Fredrik Ivars Tomas Leanderson |
| author_facet |
Per Björk Anders Björk Thomas Vogl Martin Stenström David Liberg Anders Olsson Johannes Roth Fredrik Ivars Tomas Leanderson |
| author_sort |
Per Björk |
| title |
Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. |
| title_short |
Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. |
| title_full |
Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. |
| title_fullStr |
Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. |
| title_full_unstemmed |
Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. |
| title_sort |
identification of human s100a9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2009 |
| url |
https://doaj.org/article/d9b0cf5ec37a4cefa5970058e75fe613 |
| work_keys_str_mv |
AT perbjork identificationofhumans100a9asanoveltargetfortreatmentofautoimmunediseaseviabindingtoquinoline3carboxamides AT andersbjork identificationofhumans100a9asanoveltargetfortreatmentofautoimmunediseaseviabindingtoquinoline3carboxamides AT thomasvogl identificationofhumans100a9asanoveltargetfortreatmentofautoimmunediseaseviabindingtoquinoline3carboxamides AT martinstenstrom identificationofhumans100a9asanoveltargetfortreatmentofautoimmunediseaseviabindingtoquinoline3carboxamides AT davidliberg identificationofhumans100a9asanoveltargetfortreatmentofautoimmunediseaseviabindingtoquinoline3carboxamides AT andersolsson identificationofhumans100a9asanoveltargetfortreatmentofautoimmunediseaseviabindingtoquinoline3carboxamides AT johannesroth identificationofhumans100a9asanoveltargetfortreatmentofautoimmunediseaseviabindingtoquinoline3carboxamides AT fredrikivars identificationofhumans100a9asanoveltargetfortreatmentofautoimmunediseaseviabindingtoquinoline3carboxamides AT tomasleanderson identificationofhumans100a9asanoveltargetfortreatmentofautoimmunediseaseviabindingtoquinoline3carboxamides |
| _version_ |
1718414607608971264 |